A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans.
It is traditionally held that human IgG4 MoAbs should not deplete target cells in vivo, as this isotype is inactive in a number of in vitro assays that measure effector function. We have previously challenged this dogma, and the current study was designed to investigate the in vivo biological effect...
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
1996
|